CGC Financial Services
IBRX icon

CGC Financial Services’s ImmunityBio IBRX Stock Holding History

CGC Financial Services’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18.9K Hold
2,000
– – ﹤0.01% 187
2026
Q2 		$17.5K Hold
2,000
– – ﹤0.01% 193
2026
Q1 		$15.3K Buy
+2,000
New +$13.7K ﹤0.01% 187

Other funds holding IBRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Private Advisor Group
Private Advisor Group Morristown, New Jersey $29.9B AUM 19.22% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Clearwater Capital Advisors
Clearwater Capital Advisors Hoffman Estates, Illinois $1.39B AUM 12.56% 1-Year Est. Return

CGC Financial Services's IBRX Position: Q3 2026 in Review

CGC Financial Services held its ImmunityBio (IBRX) position steady in Q3 2026 at 2,000 shares worth $18.9K. The position accounts for ﹤0.01% of the portfolio, ranked #187.

CGC Financial Services first reported a position in IBRX in Q1 2026 and has held it in 3 quarters since. 231 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • CGC Financial Services held 2,000 shares of ImmunityBio worth $18.9K as of Q3 2026.
  • CGC Financial Services left its ImmunityBio share count unchanged in Q3 2026.
  • ImmunityBio made up ﹤0.01% of CGC Financial Services's portfolio in Q3 2026, its #187 holding.
  • CGC Financial Services first reported a position in ImmunityBio in Q1 2026 and has held it in 3 quarters since.
  • 231 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on CGC Financial Services's 13F filing for Q3 2026, filed 13 Oct 2026.